Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group
Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients >70 years. The objective of the current study was to determine (i) the number of elderly (>70 years) patients with advanced/metastati...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2011-11, Vol.22 (11), p.2448-2455 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2455 |
|---|---|
| container_issue | 11 |
| container_start_page | 2448 |
| container_title | Annals of oncology |
| container_volume | 22 |
| creator | Pallis, A.G. Karampeazis, A. Vamvakas, L. Vardakis, N. Kotsakis, A. Bozionelou, V. Kalykaki, A. Hatzidaki, D. Mavroudis, D. Georgoulias, V. |
| description | Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients >70 years.
The objective of the current study was to determine (i) the number of elderly (>70 years) patients with advanced/metastatic NSCLC enrolled in phase III trials of the Hellenic Oncology Research Group, (ii) the treatment-related toxicity observed in these patients compared with their younger counterparts, and (iii) the differences in terms of response rate, time to tumor progression (TTP), and overall survival (OS) between younger and older patients.
Pooled data from five clinical trials including 1845 patients were analyzed; 1421 (77%) and 424 (23%) were |
| doi_str_mv | 10.1093/annonc/mdq772 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdq772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdq772</oup_id><els_id>S0923753419377038</els_id><sourcerecordid>10.1093/annonc/mdq772</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-9a520bcb291d3b0e46e0b5f4a6c7590a2f03ac6fa480184e03ae74b5451b0cff3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotvCkSuaCxKXUCd2vrihVWlXWlGJj3M0ccasUWIH21sUfg8_tF6lwAlxssZ-5h35GcZe5PxNzltxidY6qy6n4XtdF4_YJi-rNmu4zB-zDW8LkdWlkGfsPIRvnPOqLdqn7KzIRStEwzfs15XWRqFaAO0A0RPGiWyE6EbyaBWBseDGgTzMGE16CvDDxAN8-LTdb98CwkQRM7Q4LsEEcBq0uSOYDxgIdrsdpJTBTeYnneINjgGUs8NRxXTRLxAPBDc0jmSNglur3Oi-LvCRAqFXB7j27jg_Y090aqTnD-cF-_L-6vP2JtvfXu-27_aZkrKIWYtlwXvVF20-iJ6TrIj3pZZYqbpsORaaC1SVRtnwvJGUKqplX8oy77nSWlywbM1V3oXgSXezNxP6pct5d7Ldrba71XbiX678fOwnGv7Qv_Um4NUDgEHhqE9GTfjLyVqUTVsn7vXKpc_-d2a9opRE3BnyXVBpLYoG40nFbnDmH533AE-ulA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Pallis, A.G. ; Karampeazis, A. ; Vamvakas, L. ; Vardakis, N. ; Kotsakis, A. ; Bozionelou, V. ; Kalykaki, A. ; Hatzidaki, D. ; Mavroudis, D. ; Georgoulias, V.</creator><creatorcontrib>Pallis, A.G. ; Karampeazis, A. ; Vamvakas, L. ; Vardakis, N. ; Kotsakis, A. ; Bozionelou, V. ; Kalykaki, A. ; Hatzidaki, D. ; Mavroudis, D. ; Georgoulias, V.</creatorcontrib><description>Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients >70 years.
The objective of the current study was to determine (i) the number of elderly (>70 years) patients with advanced/metastatic NSCLC enrolled in phase III trials of the Hellenic Oncology Research Group, (ii) the treatment-related toxicity observed in these patients compared with their younger counterparts, and (iii) the differences in terms of response rate, time to tumor progression (TTP), and overall survival (OS) between younger and older patients.
Pooled data from five clinical trials including 1845 patients were analyzed; 1421 (77%) and 424 (23%) were <70 years and ≥70 years, respectively. No difference was observed in terms of the overall response rate and TTP. There was an OS difference between young and older patients, with higher risk for death in older patients. However, when the analysis was carried out after omitting a trial that showed a different trend, no difference was observed. Older patients experienced higher toxicity.
This report supports the feasibility of chemotherapy treatment for older NSCLC patients. Optimization of treatment of older NSCLC patients requires the design of prospective older-specific phase III trials for these patients.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdq772</identifier><identifier>PMID: 21393380</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Age Factors ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Clinical Trials, Phase III as Topic - methods ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Docetaxel ; Female ; geriatric oncology ; Humans ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; meta-analysis ; Multicenter Studies as Topic ; NSCLC ; older ; Pharmacology. Drug treatments ; Pneumology ; Randomized Controlled Trials as Topic - methods ; Survival Rate ; Taxoids - administration & dosage ; Taxoids - adverse effects ; Taxoids - therapeutic use ; Tumors of the respiratory system and mediastinum ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - analogs & derivatives ; Vinorelbine]]></subject><ispartof>Annals of oncology, 2011-11, Vol.22 (11), p.2448-2455</ispartof><rights>2011 European Society for Medical Oncology</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-9a520bcb291d3b0e46e0b5f4a6c7590a2f03ac6fa480184e03ae74b5451b0cff3</citedby><cites>FETCH-LOGICAL-c442t-9a520bcb291d3b0e46e0b5f4a6c7590a2f03ac6fa480184e03ae74b5451b0cff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24735897$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21393380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pallis, A.G.</creatorcontrib><creatorcontrib>Karampeazis, A.</creatorcontrib><creatorcontrib>Vamvakas, L.</creatorcontrib><creatorcontrib>Vardakis, N.</creatorcontrib><creatorcontrib>Kotsakis, A.</creatorcontrib><creatorcontrib>Bozionelou, V.</creatorcontrib><creatorcontrib>Kalykaki, A.</creatorcontrib><creatorcontrib>Hatzidaki, D.</creatorcontrib><creatorcontrib>Mavroudis, D.</creatorcontrib><creatorcontrib>Georgoulias, V.</creatorcontrib><title>Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients >70 years.
The objective of the current study was to determine (i) the number of elderly (>70 years) patients with advanced/metastatic NSCLC enrolled in phase III trials of the Hellenic Oncology Research Group, (ii) the treatment-related toxicity observed in these patients compared with their younger counterparts, and (iii) the differences in terms of response rate, time to tumor progression (TTP), and overall survival (OS) between younger and older patients.
Pooled data from five clinical trials including 1845 patients were analyzed; 1421 (77%) and 424 (23%) were <70 years and ≥70 years, respectively. No difference was observed in terms of the overall response rate and TTP. There was an OS difference between young and older patients, with higher risk for death in older patients. However, when the analysis was carried out after omitting a trial that showed a different trend, no difference was observed. Older patients experienced higher toxicity.
This report supports the feasibility of chemotherapy treatment for older NSCLC patients. Optimization of treatment of older NSCLC patients requires the design of prospective older-specific phase III trials for these patients.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Clinical Trials, Phase III as Topic - methods</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Docetaxel</subject><subject>Female</subject><subject>geriatric oncology</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>meta-analysis</subject><subject>Multicenter Studies as Topic</subject><subject>NSCLC</subject><subject>older</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - adverse effects</subject><subject>Taxoids - therapeutic use</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - analogs & derivatives</subject><subject>Vinorelbine</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EotvCkSuaCxKXUCd2vrihVWlXWlGJj3M0ccasUWIH21sUfg8_tF6lwAlxssZ-5h35GcZe5PxNzltxidY6qy6n4XtdF4_YJi-rNmu4zB-zDW8LkdWlkGfsPIRvnPOqLdqn7KzIRStEwzfs15XWRqFaAO0A0RPGiWyE6EbyaBWBseDGgTzMGE16CvDDxAN8-LTdb98CwkQRM7Q4LsEEcBq0uSOYDxgIdrsdpJTBTeYnneINjgGUs8NRxXTRLxAPBDc0jmSNglur3Oi-LvCRAqFXB7j27jg_Y090aqTnD-cF-_L-6vP2JtvfXu-27_aZkrKIWYtlwXvVF20-iJ6TrIj3pZZYqbpsORaaC1SVRtnwvJGUKqplX8oy77nSWlywbM1V3oXgSXezNxP6pct5d7Ldrba71XbiX678fOwnGv7Qv_Um4NUDgEHhqE9GTfjLyVqUTVsn7vXKpc_-d2a9opRE3BnyXVBpLYoG40nFbnDmH533AE-ulA</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Pallis, A.G.</creator><creator>Karampeazis, A.</creator><creator>Vamvakas, L.</creator><creator>Vardakis, N.</creator><creator>Kotsakis, A.</creator><creator>Bozionelou, V.</creator><creator>Kalykaki, A.</creator><creator>Hatzidaki, D.</creator><creator>Mavroudis, D.</creator><creator>Georgoulias, V.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20111101</creationdate><title>Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group</title><author>Pallis, A.G. ; Karampeazis, A. ; Vamvakas, L. ; Vardakis, N. ; Kotsakis, A. ; Bozionelou, V. ; Kalykaki, A. ; Hatzidaki, D. ; Mavroudis, D. ; Georgoulias, V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-9a520bcb291d3b0e46e0b5f4a6c7590a2f03ac6fa480184e03ae74b5451b0cff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Clinical Trials, Phase III as Topic - methods</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Docetaxel</topic><topic>Female</topic><topic>geriatric oncology</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>meta-analysis</topic><topic>Multicenter Studies as Topic</topic><topic>NSCLC</topic><topic>older</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - adverse effects</topic><topic>Taxoids - therapeutic use</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - analogs & derivatives</topic><topic>Vinorelbine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pallis, A.G.</creatorcontrib><creatorcontrib>Karampeazis, A.</creatorcontrib><creatorcontrib>Vamvakas, L.</creatorcontrib><creatorcontrib>Vardakis, N.</creatorcontrib><creatorcontrib>Kotsakis, A.</creatorcontrib><creatorcontrib>Bozionelou, V.</creatorcontrib><creatorcontrib>Kalykaki, A.</creatorcontrib><creatorcontrib>Hatzidaki, D.</creatorcontrib><creatorcontrib>Mavroudis, D.</creatorcontrib><creatorcontrib>Georgoulias, V.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pallis, A.G.</au><au>Karampeazis, A.</au><au>Vamvakas, L.</au><au>Vardakis, N.</au><au>Kotsakis, A.</au><au>Bozionelou, V.</au><au>Kalykaki, A.</au><au>Hatzidaki, D.</au><au>Mavroudis, D.</au><au>Georgoulias, V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>22</volume><issue>11</issue><spage>2448</spage><epage>2455</epage><pages>2448-2455</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients >70 years.
The objective of the current study was to determine (i) the number of elderly (>70 years) patients with advanced/metastatic NSCLC enrolled in phase III trials of the Hellenic Oncology Research Group, (ii) the treatment-related toxicity observed in these patients compared with their younger counterparts, and (iii) the differences in terms of response rate, time to tumor progression (TTP), and overall survival (OS) between younger and older patients.
Pooled data from five clinical trials including 1845 patients were analyzed; 1421 (77%) and 424 (23%) were <70 years and ≥70 years, respectively. No difference was observed in terms of the overall response rate and TTP. There was an OS difference between young and older patients, with higher risk for death in older patients. However, when the analysis was carried out after omitting a trial that showed a different trend, no difference was observed. Older patients experienced higher toxicity.
This report supports the feasibility of chemotherapy treatment for older NSCLC patients. Optimization of treatment of older NSCLC patients requires the design of prospective older-specific phase III trials for these patients.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>21393380</pmid><doi>10.1093/annonc/mdq772</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2011-11, Vol.22 (11), p.2448-2455 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdq772 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Age Factors Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Trials, Phase III as Topic - methods Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Docetaxel Female geriatric oncology Humans Lung Neoplasms - drug therapy Male Medical sciences meta-analysis Multicenter Studies as Topic NSCLC older Pharmacology. Drug treatments Pneumology Randomized Controlled Trials as Topic - methods Survival Rate Taxoids - administration & dosage Taxoids - adverse effects Taxoids - therapeutic use Tumors of the respiratory system and mediastinum Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - analogs & derivatives Vinorelbine |
| title | Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A18%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20treatment%20tolerance%20in%20older%20patients%20with%20NSCLC:%20a%20meta-analysis%20of%20five%20phase%20III%20randomized%20trials%20conducted%20by%20the%20Hellenic%20Oncology%20Research%20Group&rft.jtitle=Annals%20of%20oncology&rft.au=Pallis,%20A.G.&rft.date=2011-11-01&rft.volume=22&rft.issue=11&rft.spage=2448&rft.epage=2455&rft.pages=2448-2455&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdq772&rft_dat=%3Coup_cross%3E10.1093/annonc/mdq772%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21393380&rft_oup_id=10.1093/annonc/mdq772&rft_els_id=S0923753419377038&rfr_iscdi=true |